

## Index

- A. niger* 149  
*A. versicolor* 149  
 Abciximab 342  
 Ablynx 345  
 Absorption 77  
   – enhancers 78  
   – disadvantage of 78  
 ABT-229 273  
 ABY-002 344  
 AC187 297, 299, 300  
 Acetaminophen 298  
 Acetylcholine binding protein (AChBP) 128  
 Acetylcholine receptor (AChR) 328  
 Acinetobacter baumannii 64, 91, 107, 109  
 Acne vulgaris, treatment of 166–67  
 Acquired immune deficiency syndrome (AIDS) 45  
 Activated carbonyl inhibitors 17  
 Acylated ghrelin 259, 270  
 Acylated KTP derivative 178  
 Acylcarnitines 79  
 Adalimumab 337, 347  
 ADAMB. *See* Dermorphin  
 Adnectins 350  
 Adrenocorticotrophic hormone (ACTH) 250  
 Aesculus hippocastanum 141  
 Affibodies 350  
 Aggregation 73  
 Agonists 175  
 Agouti-related protein (AGRP) 252  
 Agouti-signaling protein (ASIP) 252  
 AIDS symptomatic stage 238  
 L-Alanine 317  
*Alcea rosea* 144  
 Alexion Pharmaceuticals 343  
 Alfalfa antifungal peptide (alfAFP) 149  
 Aliskirin<sup>®</sup> 44  
 Alkanoylcholines 79  
*Aloe vera* gel 78, 80  
*Alternaria helianthi* 148  
 ALX-0018 344  
 ALX-0061 344  
 ALX-0141 344  
 ALX-0681 344  
 N-amidino-YrF-Me $\beta$ Ala-OH 176  
 2-amino-2-hydroxy-methyl-1,3-propanediol 81  
 (1R,2S)-1-amino-2-vinyl-cyclopropyl carboxylic acid (vinyl-ACCA)-containing inhibitors 29  
 2-amino-4-thiazolyl-group 43  
 1-aminocyclopropyl carboxylic acid (ACCA) 22  
 AMPbiotech 57  
 Amphipacity 141  
 Amygdala 249  
 $\alpha$ -amylases 141  
 Amylin 256–57, 295  
   – anorexigenic effect 257  
   – humans, amylin agonism in 295–309  
 Amylin agonism, translational research on 295–309  
   – amylin physiology, overview of 295  
   – insulin-dependent diabetes 297–99  
     -- gastric emptying and amylin agonism 298–99  
     -- gastric emptying and diabetes 298  
     -- glucagon and amylin agonism 297–98  
     -- post-prandial hyperglucagonemia and diabetes 297  
   – obesity, translational research in 299–309  
     -- amylin agonism-based translational research 307–9  
     -- clinical studies 302–3  
     -- combination studies 304  
     -- combined amylin and leptin agonism 305–7  
     -- endogenous amylin, role of 299–300

- Amylin agonism, translational research on (*continued*)
  - pre-clinical studies 300–302
  - small molecule agents, and amylin agonism 304
  - pramlintide 296
- Amylin monotherapy 301
- Amylin physiology, overview of 295
- Amylin receptor (AMY) 256
- Amylin-induced weight loss versus caloric restriction 300
- Analgesia 172
- L-V13K<sub>L</sub> analogs 105
- Angiocept 344
- Angiotensin converting enzyme (ACE) 38
- Angiotensin II 38
- Anionic polymers 79
- Anorexia 284
- Anorexigenic effects, of amylin 300
- Antagonists 175
  - δ-antagonists 176
- Antibiotics 166
- Antibodies 337–50
  - fragments 341–43
  - intracellular 347–50
  - immunogenicity of engineered antibodies 348–49
  - new protein scaffolds, developing 349–50
  - multivalent, bispecific, and bifunctional fragments, engineering of 345–47
  - single-domain antibodies 343–45
  - structure 338–41
- Antibody-dependent cellular cytotoxicity (ADCC) 338
- Anticalins 350
- Anti-CD20 antibody (Rituxan<sup>®</sup>) 200
- Antigen-presenting cells (APC) 319
- Antigens and vaccines
  - peptides as 314–15
- Anti-HIV-1 therapeutics 209
- Antimicrobial peptides (AMP or AMPs) 91–114, 139
  - amphipathic α-helical antimicrobial peptides
  - antimicrobial and hemolytic activities of 92–94
  - structure–activity relationship (SAR) studies of 94–112
  - commercialization 112–13
  - cyclic β-sheet antimicrobial peptides
  - structure–activity relationship (SAR) studies of 94–112
  - marketing of 57–68
  - basic research 58–60
  - costs for patenting 63
  - patents 61–63
  - potential applications of 63–64
  - spin-off creation 66–68
  - technology transfer 64–66
  - therapeutic potential 113–14
- Antiviral inhibitors, identification and characterization of 7
- Apical epithelial cell membrane 74
- Aplastic anemia (AA) 200
- Arabidopsis* 148
- Arabidopsis thaliana* 150
- Arcuate nucleus (ARC) 250
- Area postrema (AP) 247, 257, 295
- L-Arg 177
- Arginine 233
- Arginine tolerance test 297
- L-arginine vasopressin 75
- β-arrestin 273
- Astrocytes 321
- ATN-103 344
- Autoimmune disorders 315
- Avastin 339
- Azathioprine 200, 202
- Azithromycin 283
- B cell epitopes 314
- Bacterially expressed peptides 220
- Bacteriophage 314
- Barrel-stave model 92
- Basal epithelial cell membrane 74
- Bed nucleus of the stria terminalis (BNST) 249
- Benzoyl peroxide 166
- Benzoylation 60
- Benzyl-methoxyproline 18, 22
- Beta-barrelin 140
- Bexxar 339, 346
- BI00201335 29, 30, 31
- Bifunctional antibodies 346
- BILA 2157 44
- BILD 1257 35
- BILD 1263 36
- Bile salts 79
- BILN 2061 29
- BILN 2061 (ciluprevir) 28
- BioBreeding rats 298
- Biological delivery system 174
- Biotechnological products, from Plant AMPs 144–50
- Biphalin 175, 176
- Bispecific antibodies 345–46
- Blood–brain barrier (BBB) 174, 321
- Body mass index (BMI) 247
- Bombesin and Gastrin-Releasing Peptide 257–58
- Bombesin receptor subtype 3 (BRS-3) 257

- Bombesin-like peptides 257–58  
*Botrytis cinerea* 140, 148  
 BP015 peptide 58  
 BP021 peptide 58  
 BP76 peptide 60  
 BP77 peptide 60  
 BP78 peptide 60  
 BP100 peptide 58, 59  
 BP102 peptide 60  
 BP103 peptide 60  
 BP125 peptide 60  
 BP126 peptide 60  
 Bracelet 141  
 Brain derived neurotrophic factor (BDNF) 322  
 Brain, neurotropic factors in  
 – neuroprotection and augmentation of 321–23  
 Breath method  
 – [<sup>13</sup>C]-octanoic acid 284  
 Brief ITP primer 199–201  
 BRS-3 agonists 257  
 Brush border membrane bound enzymes and intracellular enzymes 76  
 Bupropion (Contrace) 255  
 Butanediamide 43
- C34 211–13, 218, 220, 221  
 C34coil 219  
 C52L 220  
 Cachexia 270  
 Caco-2 cells 176  
 Calcitonin receptor (CT)  
 – splicing isoforms 256  
 Campath 339  
 CaMV35S 149  
 Cancer anorexia 284  
*Candida albicans* 150  
*Capsicum chinense* 150  
 Carbohydrate binding-domains 143  
 Carbopol 79  
 Carcinoembryonic antigen (CEA) 314  
 Carpet pore model 92  
 Cathelicidins 92  
 Catheter-related infections, prevention of 165–66  
 Cationic polymers 79  
 Cationicity 141  
 Cationization 178  
 (CCIZN17)<sub>3</sub> 222  
 CCK2R 258  
 CCK-AR 258  
 CCR5 210  
 CD4 210  
 CD4-BFFI 221–22
- cDNA 120–21  
 CDR grafting 348, 349  
 CDR-grafting based humanization method 348  
 CECMEL11 library 58, 59  
 Cell penetrating proteins 81  
 β-cell dysregulation 295  
 α-cells 297, 298  
 Centocor 342  
 Central nervous system (CNS)  
 analgesia 172  
 Centrally secreted neuropeptide systems  
 – corticotropin releasing factor 248–56  
 – melanin concentrating hormone (MCH) 249–50  
 – melanocortins 250–52  
 – neuromedin S (NMS) 254–55  
 – neuromedin U (NMU) 254–55  
 – neuropeptide Y (NPY) 252–54  
 – opioids 255–56  
 – QRFP 256  
 Cephalexin 72  
 Certolizumab pegol 339  
 Chaperones 148  
 Chelating agents 79  
 Chemical delivery system 174  
 Chemokine receptors 210  
 Chemotherapy-induced thrombocytopenia (CIT) 200  
 Chitin-binding scaffolds 143  
 Chitosan 79, 84  
 CHO cells 273  
 Cholecystokinin (CCK) 258–59, 307  
 Chronic intestinal pseudoobstruction 279  
 Chronic relapsing EAE (CR-EAE) 317  
 Cyclooxygenase 1 179  
 Cyclooxygenase 2 179  
 CIDS AV 57  
 Cimzia 342  
 Circular dichroism (CD) 96, 102  
 Cisapride 283  
*Clavibacter michiganensis* subsp. *sepedonicus* 148  
 Clindamycin 164  
 c-Mpl 189  
<sup>13</sup>C NMR spin–lattice relaxation experiments 21  
 CNS delivery 174  
 Cocaine-amphetamine-related transcript (CART) 252  
*Colletotrichum coccoides* 148  
 Combinatorial protein engineering 349  
 Combined amylin and leptin agonism 305–7  
 Complementarity determining region (CDR)1 329

- Complement-dependent cytotoxicity (CDC) 338
- Concentration effect 179
- Cone snails* 119–20
- Conopeptides 119
- Conotoxin
  - classification and targets 121–22
  - discovery and characterization 120–21
  - as drug leads 128–33
  - $\omega$ -conotoxins 129–30, 130–31
  - in drug design 128–29
  - re-engineered conotoxins, in drug design 131–33
  - folding 127
  - synthesis 124–27
- Conotoxin-based leads, in drug design 119–33
  - classification and targets 121–22
  - cone snails 119–20
  - discovery and characterization 120–21
  - drug discovery, prospects for 124
  - folding 127
  - posttranslational modifications 122–24
  - structure by NMR and X-Ray 127–28
  - synthesis 124–27
- $\alpha$ -conotoxins 121, 129–30, 130–31
- Conus geographus* 120
- Conus magus* 129
- Conus marmoreus* 130
- Conus victoriae* 130
- Copaxone 316, 318
- Copolymer 1 (Cop 1) 316
  - clinical studies with MS patients 317–18
  - development of 316–27
  - immunological mechanisms involved in mitigation of disease by 318–20
  - immunomodulation, in CNS 320–21
  - inflammatory bowel disease, effect on 326–27
  - myelin repair and neurogenesis 323–26
  - neuroprotection and augmentation of
    - neurotropic factors in brain 321–23
- Corticosteroids 202
- Corticotropin releasing factor (CRF) 248–56, 248–49
- CP32M 218
- CP621–652 218
- Cremophor EL 79
- Crohn's disease (CD) 326
  - $^{13}\text{C}$  spin–lattice relaxation measurements 13
- C-terminal acid 17, 18
- C-terminal carboxyl derivatives 18
- C-terminal carboxylate inhibitor 18
- C-terminal carboxylic acid 29
- C-terminal warhead 15
- C-terminally conjugated Fc-peptide-peptide (Fc-TMP-TMP) 194
- C-termini 144
- Curvularia* spp 148
- CVID 129
- CXCR4 210
- Cyclic nausea and vomiting 282
- Cyclic peptides 59
- Cyclic vomiting syndrome (CVS) 282
- Cyclic  $\beta$ -sheet peptides 113
- Cyclization 143
- Cyclosporin 171, 200
- Cyclosporin A 79, 315, 320
- Cyclotides 140, 141, 143
- Cysteines 141
- Cysteine-stabilized  $\alpha\beta$  motifs (CS $\alpha\beta$ ) 141
- Cytochrome P450 enzyme (CYP3A4) 270
- Cytotoxic T-cell (CTL) 314
- D&D drug 183
- [D-Ala<sup>2</sup>, N-MePhe<sup>4</sup>, Gly-ol]-enkephalin] (DAMGO) 255
- [D-Pen<sup>2</sup>, D-Pen<sup>5</sup>]-enkephalin (DPDPE) 175
- D1 analogs, biological activity of 109
- D1(V13) and D16(K13, K16), helical net representations for 111
- D16 107–10
- Dalacin T<sup>®</sup> 164
- DALDA. *see* Dermorphin
- Danazol 202
- DARPinS 350
- DDIVPC as an inhibitor of NS3 protease 16–18
- Decapeptide angiotensin I 38
- Defensin-1 (pth1) gene 148
- Defensins 92, 140, 141, 143
- Degradation
  - intracellular peptide degradation 76
  - by luminal enzymes 76
  - proteolytic 76
- Demyelination 324
- Denazol 200
- Dermorphin 175, 176
- Des-acyl ghrelin 259
- Dextran sulfate sodium (DSS)-induced colitis 326
- Diabetes
  - and gastric emptying 298
  - post-prandial hyperglucagonemia and 297
- Diabetes mellitus
  - type 1 295, 298
  - peptides therapy for 327–28
  - type 2 (T2DM) 261, 295, 298
- Diabetes-associated peptide (DAP) 256
- Diabetic gastroparesis 274, 277, 281, 284

- DiaPep277 327  
 Diet-induced obese (DIO) prone 300  
 Differential line-broadening (DLB)  
   method 8, 18  
*N,N*-dimethylacetamide side chain 43  
*N,N*-dimethylamide fragment 44  
 Dimethylformamide (DMF) 126  
 2',6'-dimethyltyrosine 176  
 DIO ovariectomized (OVX) rat model 307  
 DioRaSSP<sup>®</sup> (Diosynth Rapid Solution  
   Synthesis of Peptides) 172  
 Dipeptide isostere 45  
 Dipeptidyl peptidase-IV (DPP-IV) 260  
 DIPP-NH<sub>2</sub>[ψ] 176  
 Disulfide-poor peptides 119  
 Disulfide-rich peptides 119  
 Dmt-Ticψ[CH<sub>2</sub>NH]Phe-Phe-NH<sub>2</sub> 176  
 [Dmt<sup>1</sup>]DALDA 176  
 Dom-0200/ART621 344  
 Domantis 345  
 Domperidone 283  
 Dorsal root ganglion (DRG) 130  
 DP107 211  
 DP-178. *See* Enfuvirtide  
 DPDPE. *See* Enkephalin  
 D-peptides 219  
 Drug candidates, peptides as 327–29  
 Drug delivery enhancement, multiple  
   approaches for 174  
 Drug discovery, prospects for 124  
 Dual-altered peptide ligand (APL) 328  
 D-V13K (D1) 106  
 Dyax 350  
 Dynorphins 173  
 Dyslipidemia 300
- Ecallantide 350  
 Eculizumab 339  
 Efflux inhibitors 79  
 Efflux transport systems 76–77  
 Electrogastrography 282  
 Enkephalitic protein 316  
 Endogenous amylin, role of 299–300  
 Endogenous peptides and their  
   receptors 247–63  
   – centrally secreted neuropeptide systems  
   -- corticotropin releasing factor 248–56  
   -- melanin concentrating hormone  
   (MCH) 249–50  
   -- melanocortins 250–52  
   -- neuromedin S (NMS) 254–55  
   -- neuromedin U (NMU) 254–55  
   -- neuropeptide Y (NPY) 252–54  
   -- opioids 255–56  
   -- QRFP 256  
   – peripherally secreted neuropeptides  
   256–63  
   -- amylin 256–57  
   -- bombesin-like peptides 257–58  
   -- cholecystokinin (CCK) 258–59  
   -- ghrelin 259–60  
   -- glucagon-like peptide-1 (GLP-1) 260–61  
   -- leptin 261–62  
   -- oxyntomodulin (OXM) 262  
   -- PYY3-36 and pancreatic polypeptide  
   (PP) 262–63  
 Endogenous peptides into new  
   analgesics 171–84  
 Endomitoses 189  
 Endomorphin-1 (EM-1) 173  
 Endomorphin-2 (EM-2) 173  
 Endomorphins 173, 175  
   – versus typical opioids 173  
 Endorphins 173  
 Enfuvirtide 172, 211, 213–14, 216, 217, 218,  
   220, 222–23, 232  
 Engineered Kunitz-type inhibitors 350  
 Enkephalin 173, 175, 179  
*Enterobacter* species 64, 91  
*Enterococcus faecalis* 106  
*Enterococcus faecium* 63  
*Enterococcus faecium* 91  
 Enterocytes 74  
 Enzyme inhibition 84  
 Epoetin alfa (Eprex<sup>®</sup>) 190  
 Eptifibatide 172  
 Erbitux 339  
*Erwinia amylovora* 58, 59  
 Erythromycin 270, 273, 274, 275, 279, 281,  
   282, 283  
 Erythropoietin receptor (EpoR) 192  
 ESBA105, 344  
*Escherichia coli* 64, 146, 147, 148, 149  
 ESKAPE microorganisms 63, 91  
 Estradiol 307  
 Ethylene glycol-bis(2-aminoethylether)-*N,N,N,N*-  
   tetraacetic acid (EGTA) 79  
*Eucommia ulmoides* 143  
 Eukaryotic cell membrane  
   – and antimicrobial peptides 93  
 Eukaryotic system 146  
 EX-1314 276  
 EX-1315 276  
 Excallantide 344  
 Experimental autoimmune encephalomyelitis  
   (EAE) 316  
 Experimental autoimmune MG  
   (EAMG) 328  
 Extracellular signal regulated kinase  
   (ERK) 261

- Fatty acids 79
- Fatty Zucker rats 298
- Fire blight 59
- FK-506 peptide 315, 320
- Flexible apo receptor 14
- Fluoren-9-ylmethoxycarbonyl (Fmoc) 126
- Fluorescein isothiocyanate labeled dextran (FD-4) 74
- Fluorescence spectroscopy 179
- Fluoroketone 12
- Food intake and body weight
- clinical studies 302–3
  - endogenous amylin, role of 299–300
  - pre-clinical studies 300–302
- Förster resonance energy transfer (FRET) 236
- Functional dyspepsia (FD) 282–83, 282
- Fusarium graminearum* 149
- Fusarium moniliforme* 148
- Fusarium oxysporum* 140
- Fusarium oxysporum* f. sp. *vasinfectum* 148
- Fusarium solani* 149
- Fusion inhibitor peptides, of HIV 215–22
- bacterially expressed peptides 220
  - helicity increase and binding to gp41 216–19
  - isomeric peptides and resistance to proteolysis 219–20
  - peptides modification by derivatization with lipids/proteins 220–22
- FusoGen Pharmaceuticals Inc. 215
- Fuzeon. *See* Enfuvirtide
- G protein-coupled receptors (GPCR) 249, 269
- Gastric emptying 297
- and amylin agonism 298–99
  - and diabetes 298
- Gastric emptying, delayed
- critically ill patients with 279
- Gastric MMCs 270
- Gastro-esophageal reflux disease (GERD) 278, 283–84
- Gastrointestinal (GI) motility 269
- Gastrointestinal tract 72
- Gastrointestinal tract, biochemical barriers of 75–76
- brush border membrane bound enzymes and intracellular enzymes 76
  - luminal enzymes 76
- Gastrointestinal tract, physical barriers of 73–75
- paracellular pathway 75
  - transcellular pathway 73–74
  - apical epithelial cell membrane 74
  - basal epithelial cell membrane 74
  - unstirred water layer 73–74
- Gastrointestinal tract, strategies to overcome barriers of 77–84
- absorption enhancing agents 77–78
  - chemical and physical modifications 78–81
  - targeting receptors and transporters 82–83
  - targeting specific regions of the gastrointestinal tract 81–82
  - enzyme inhibition 84
  - formulation strategies 83–84
  - mucoadhesive systems 84
  - particulate carrier systems 83–84
- Gastrointestinal transit time and site-specific absorption 77
- Gastroparesis 283
- Gastroparesis Cardinal Symptom Index 277
- Gastroparesis, meaning of 279
- Gastroparesis, patients with 279–84
- anorexia and decreased appetite 284
  - cyclic nausea and vomiting 282
  - diabetic gastroparesis 281
  - functional dyspepsia (FD) 282–83
  - gastro-esophageal reflux disease (GERD) 283–84
  - migraine 282
  - Parkinson's disease 281–82
- Gaviscon 283
- Genentech 342
- GERD 283
- Ghrelin 259–60, 270, 271, 276–77, 284
- assays relevant to non-GI activity 276–77
  - assays relevant to the therapeutic mechanism of action 276
  - clinical development of 284–85
  - clinical potential of 270–71
- Ghrelin and motilin, similarities and differences between 269–70
- Ghrelin mRNA 269
- Ghrelin O-acyltransferase (GOAT) 259
- Ghrelin receptor 269
- Ghrelin receptor agonists 276, 285
- Ghrelin system 269
- Ghrelin, forms of 270
- Glatiramer acetate (GA) 316, 318
- GlaxoSmithKline 346
- GLP-1. *See* Glucagon-like peptide-1 (GLP-1)
- Glucagon, and amylin agonism 297–98
- Glucagon-like peptide-1 (GLP-1) 260–61, 260
- GLP-1 receptor (GLP-1R) 260
- Glucose-stimulated insulin secretion (GSIS) 258
- Glutamic acid 233
- L-glutamic acid 313, 317
- Glutathione S-transferase (GST) 148

- Glycocalyx 73, 74  
 Glycosylation 175  
 GM-109 275  
 Golimumab 339, 347  
 gp120-CD4 binding 210, 211  
 gp120-coreceptors binding inhibitors 211  
 gp41 210, 215, 216–19  
 GPR38 269  
 G-protein receptor kinases 273  
 Graft against host (GVH) 320  
 Gramicidin S (GS) 95–96, 95, 103  
 Gram-negative bacteria 58, 63  
 Gram-positive bacteria 58, 63, 106  
 Growth hormone secretagogue receptor  
 type-1a (GHS-R1a) 259  
 Growth hormone secretagogues 276  
 GS12 (cyclo-(VKLKY<sub>d</sub>PKVKLY<sub>d</sub>P) 96  
 GS14 (cyclo-(VKLVY<sub>d</sub>PLKVKLY<sub>d</sub>P) 95–96  
 GS14K4 (cyclo-(VKLK<sub>d</sub>VY<sub>d</sub>PLKVKLY<sub>d</sub>P) 96  
 GSK962040 274  
 Guinea-pigs 276
- H<sub>2</sub> receptor antagonists (H<sub>2</sub>RAs) 283  
 HCMV protease. *See* Human cytomegalovirus  
 (HCMV) protease  
 HCV. *See* Hepatitis C virus  
 Heat-shock proteins (HSP) 327  
 HeLa 150  
 α-helical peptides 113  
 α-helices 144  
 Hemagglutinin (HA) 79  
 Hepatitis C virus (HCV) 15–32  
 – as an antiviral target 15  
 – BI00201335 29–32  
 – DDIVPC as an inhibitor of NS3  
 protease 16–18  
 – knowledge building 18–21  
 – macrocyclization 25–29  
 – NS3 serine protease 16  
 – N-terminal truncation and improved P1, P2  
 and P5 substituents 22–25  
 – “sensemaking” and knowledge building  
 phase 18  
 Her2/neu 315  
 Herceptin 339  
 Heroin 174  
 Herpes simplex virus 32–38  
 – ribonucleotide reductase inhibitors 32–38  
 Heterologous plant antimicrobial defensins,  
 production of 147  
 Hevein-like AMPs 140  
 Hexyl insulin mono-conjugate 2 (HIM2) 81  
 High fat diet (HFD) 259  
 Hippocampal neurogenesis 308  
 HIV. *See* Human immunodeficiency virus  
 (HIV)  
 HIV protease inhibitors 45–47  
 HIV-1  
 – fusion inhibitor 232  
 HIV-1 gp41 232  
 HIV35 216  
 Hoffmann-La Roche, Inc. 211  
 Hollyhock 144  
 Hordeum vulgareum 141  
 Host defense peptide 92  
 Humalog 172  
 Human anti-chimeric antibody  
 (HACA) 337  
 Human anti-human antibodies  
 (HAHAs) 337  
 Human anti-mouse antibodies  
 (HAMAs) 337, 348  
 Human cytomegalovirus (HCMV)  
 protease 7–15  
 – antiviral inhibitors, identification and  
 characterization of 7  
 – determining structures of ligands bound  
 to 8–10  
 – ligand adaptations upon binding 12–14  
 – optimized peptidyl segment 10–12  
 – SAR studies 10  
 – strategic summary 14–15  
 Human immunodeficiency virus (HIV) 140,  
 209, 314  
 – drug-resistance and combination  
 therapy 222–23  
 – entry and inhibition 210–11  
 – HIV-1 envelope protein 209–10  
 – HIV-1 fusion inhibitors 211–15  
 – HIV-1 infection 231  
 – HIV protease inhibitors 45–47  
 – HIV-1  
 – fusion inhibitor 232  
 – HIV-1 gp41 232  
 – new fusion inhibitor peptides,  
 creating 215–22  
 Human leukocyte elastase (HLE) 18  
 Humanized antibodies 337, 338  
 Humira 339  
 Hydrofluoric acid (HF) 126  
 Hydrophilicity of peptide drugs 73  
 Hyperglycemia 279  
 Hyperinsulinemia 295, 300  
 Hypermotility 298  
 Hypoglycemic override mechanism 298
- IBS 283  
 Ibuprofen (IBP) 178, 179, 181

- Ibuprofen-KTP-amide (IKTP-NH<sub>2</sub>) 178, 179, 181  
 IFN- $\gamma$  321  
 IFN- $\beta$  315  
 IgNAR 343  
 IL-10 320, 321  
 IL-4 320  
 Immune thrombocytopenic purpura (ITP) 189  
 Immunogenicity 338  
 Immunoglobulin G (IgG) 340, 341  
 Immunoglobulins 192  
 Immunomodulators  
 – peptides as 315–16  
 Immunomodulatory peptides, additional  
 – as drug candidates 327–29  
 Impatiens 140  
 Inclusion bodies (IBs) 147  
 Incomplete Freund's adjuvant (IFA) 316  
 Indolicidin 159, 160  
 "Induced fit" model 7  
 Inflammation 270  
 Inflammatory bowel disease (IBD) 326  
 – Copolymer 1 (Cop 1) effect on 326–27  
 Influenza virus 314  
 Insulin 75, 171, 295  
 Insulin monotherapy 295  
 Insulin therapy 279  
 Insulin-dependent diabetes, translational research in 297–99  
 – amylin agonism and gastric emptying 298–99  
 – amylin agonism and glucagon 297–98  
 – gastric emptying and diabetes 298  
 – post-prandial hyperglucagonemia and diabetes 297  
 Integrilin (eptifibatide) 172  
 Interferon (IFN) 315  
 – IFN- $\alpha$  30  
 Intestinal epithelium, transport pathways across 72–73  
 Intrabodies. *See* Intracellular antibodies  
 Intracellular antibodies 347–50  
 Intracerebroventricular (icv) 260  
 Intranasal delivery system 172  
 IQN17 219  
 Islet amyloid polypeptide (IAPP) 256  
 Isotretinoin therapy 166  
  
 Janus-kinase 2 (Jak2) 261  
 Januvia (sitagliptin) 261  
  
 Kalata B8 143  
 Kalata-B1 143  
  
 Kalbitor/DX-88 350  
*Klebsiella pneumoniae* 64, 91  
 Knottins 140  
 KTP-amide (KTP-NH<sub>2</sub>) 178, 179, 181  
 KTP-K-palmitoyl 178  
 Kyotorphin (KTP) 177  
 Kyotorphin derivatives 171–84  
 – academia and pharmaceutical industry 183–84  
 – BBB permeability, with peptide–membrane partition studies 179  
 – central nervous system analgesic peptides 172–73  
 – delivering analgesic peptides to brain 174–75  
 – endogenous dipeptide, potential of 177–78  
 – endogenous opioid system 173–74  
 – future drug candidates, peptides as 171–72  
 – new KTP derivatives 178–79  
 – new opioid-derived peptides, development of 175–77  
 – partition to membrane and enhanced analgesic activity 179–83  
  
 $\beta$ -lactam antibiotics 72  
 Lacy mutants 147  
 Lansoprazole 283  
 Large unilamellar vesicles (LUVs) 179  
 Lateral septum 249  
 Leptin 261–62, 300, 305, 307  
 [Leu<sup>13</sup>]-motilin 275  
 Leucin enkephalin 75  
 Licensing 64–66, 65  
 Ligand adaptations upon binding 12–14  
 Lipid-transfer proteins 140  
 Lipophilicity 178, 183  
 Liposomes 83  
 LIPPSO 57  
 Liquid chromatography-mass spectrometry (LC-MS) 121  
 Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 238  
 L-Lysine 317  
 Lower esophageal sphincter (LES) 278  
 Lucentis 339  
 Luminal enzymes 76  
 Lytic enzymes 177  
  
*M. cochincinensis* 143  
 Macrocyclic inhibitor 25  
 Macrocyclization 25–29, 25, 26  
 Macrolides 271

- MAGE 315
- Maltose-binding protein (MBP) 148
- Mammalian and microbial cellular membranes, AMP selectivity between 93–94
- Mammalian cell culture 149
- MAR study 150
- Mass spectrometry (MS) 120–21
- MBI 226. *See* Omiganan pentahydrochloride
- MC3 receptor 250
- MC4 receptor 252
- MCHR1 249
- MCHR2 250
- Median preoptic nucleus 249
- Medicago sativa 149
- Megakaryocytes 189
- Megestrol 284
- Megestrol acetate 284
- Melanin concentrating hormone (MCH) 249–50
- Melanocortins 250–52
- $\alpha$ -melanocyte stimulating hormone ( $\alpha$ -MSH) 250
- Melittin 80
- Membrane transduction peptides. *See* Cell penetrating proteins
- Membrane translocating sequences. *See* Cell penetrating proteins
- Met-enkephalin 177
- Methicillin-resistant *Staphylococcus aureus* (MRSA) 163
- Methotrexate 338
- N-methyl-2-pyrindylethyl-substituent 44
- Methyl ketones 12
- Methylotrophic yeast 148
- Metoclopramide 279, 282, 283
- Metreleptin 257, 299, 304, 306
- Microbial fermentation 149
- Migraine 282
- Migrating motor complex (MMC) 269
- Mitemincal 274, 281, 284, 285
- Mitogen-activated protein (MAP) 255
- Möbius 141
- Molecular size, of peptide drugs 73
- Monoclonal antibodies 338
- Monoclonal human IgG 316
- Morphiceptin 75
- Morphine 173, 176
- Mosapride 283
- Motilide mitemincal 284
- Motilides 271
- Motilin 269, 270, 271–76, 273, 274
- and ghrelin, similarities and differences between 269–70
- assays relevant to possible non-GI activity 275–76
- assays relevant to the therapeutic mechanism of action 271–75
- clinical development of 284–85
- clinical potential of 270–71
- Motilin receptor 269
- Motilin receptor agonist 274
- Motilin receptor agonist GSK962040 284
- Motilin receptor antagonist 275
- MP0112 344
- M-site peptide 9
- MT103 344
- MT110 344
- MUC-1 315
- Mucoadhesive systems 84
- Multiple sclerosis (MS) 316
- Copolymer 1 (Cop 1) in 317–18
- polypeptide immunomodulator drug, for treatment of 316–27
- Multiple system atrophy (MSA) 281
- Muramyl dipptide (MDP) 315
- Murine monoclonal antibodies 348
- MVIIA 129
- MX-594AN. *See* Omiganan pentahydrochloride
- Myasthenia gravis (MG)
- peptides therapy for 328
- Myelin basic protein (MBP) 316
- Myelin oligodendrocyte glycoprotein (MOG) 316
- Myelin proteolipid protein (PLP) 316
- Myelin repair and neurogenesis 323–26
- Mylotarg 339, 346
- Myrosinase-binding proteins type 1 (MBP-1) 140
- N. crassa* 149
- N36 211, 215, 216, 217
- Naloxone 175, 177
- Naltrexone 255
- Naphthyl-methoxyproline 22
- Napin 143
- Nasogastric feeding 279
- National Institutes of Health 183
- Neonatal Fc receptor (FcRn) 192
- Neosporin 91
- Neuromedin S (NMS) 254–55
- Neuromedin U (NMU) 254–55
- Neuronal nicotinic acetylcholine receptor (nAChR) 121, 129
- Neuronal noradrenaline transporter (NET) 130
- Neuronal progenitor cells (NPCs) 323

- Neuropeptide Y (NPY) 252–54  
 Neuropeptides 247  
 Neuropsychiatric disease, treatment of  
 – amylin agonism in 307  
 Neurotrophin (NT) 323  
*Nicotiana alata* 140, 141  
 Nitric oxide (NO) synthase 177  
 [Nle<sup>13</sup>]-motilin 274  
 NMR ROESY experiment 21  
 NMUR1 254  
 NMUR2 254  
 Nobex<sup>®</sup> Corporation 81  
 NOESY (nuclear Overhauser spectroscopy) 11, 17, 18  
 – transferred NOESY model 25  
 Non-acylated ghrelin 270  
 Non-encephalogenic protein 316  
 Non-enzymatic degradation of peptides 73  
 Non-polar face and polar face substituted peptide analogs, antimicrobial activity and hemolytic activity of 101  
 Non-structural (NS) proteins 15  
 Nonylphenoxypoly-oxyethylene 79  
 Normoglycemia 298  
 N-peptide inhibitors 211  
 NS3 protease inhibitors 29  
 NS3 serine protease 16  
 NSAIDS (non-steroidal anti-inflammatory drugs) 183  
 N-terminal cleavage products 16, 17  
 N-terminal truncation and improved P1, P2 and P5 substituents 22–25  
 N-terminus, modifications at 34  
 Nuclear magnetic resonance (NMR) 6, 7, 8, 127
- Obesity 247  
 Obesity, translational research in 299–309  
 – amylin agonism and small molecule agents 304  
 – amylin agonism-based translational research 307–9  
 – combination studies 304  
 – combined amylin and leptin agonism 305–7  
 – food intake and body weight  
 -- clinical studies 302–3  
 -- endogenous amylin, role of 299–300  
 -- pre-clinical studies 300–302  
 Obinaptide 263  
 Octapeptide angiotensin II 38  
 OKT3 339
- Oligodendrocyte progenitor cells (OPCs) 323  
 Omiganan pentahydrochloride 159–67  
 – clinical studies 165–67  
 – for topical indications 159–60  
 – minimal inhibitory concentrations (MIC) 162  
 – preclinical efficacy studies 163–64  
 – preclinical toxicology studies 164–65  
 – spectrum of activity 163  
 – structure and mechanism of action 160–63  
 Omiganan-induced killing 162  
 Omigard<sup>™</sup> 160  
 Onglyza (Saxagliptin) 261  
 Opioid-like drugs 183  
 $\mu$ -opioid receptor (MOR) 173, 176  
 $\delta$ -opioid receptor 176  
 $\kappa$ -opioid receptors 176  
 Opioids 255–56  
 Opium 173  
 Optimized peptidyl segment 10–12  
 Oral peptide drug delivery 71–85  
 – challenges associated with 72–77  
 -- efflux transport systems 76–77  
 -- gastrointestinal tract, biochemical barriers of 75–76  
 -- gastrointestinal tract, physical barriers of 73–75  
 -- gastrointestinal transit time and site-specific absorption 77  
 -- transport pathways across intestinal epithelium 72–73  
 -- unfavorable physicochemical properties 73  
 – gastrointestinal tract, strategies to overcome barriers of 77–84  
 -- absorption enhancing agents 77–78  
 -- chemical and physical modifications 78–81  
 -- formulation strategies 83–84  
 -- targeting receptors and transporters 82–83  
 -- targeting specific regions of the gastrointestinal tract 81–82  
 Ornamental tobacco 140  
 Oxyntomodulin (OXM) 260, 262  
 Oxytocin 171
- P. guajava* 144  
*P. personata* 148  
 P1 ACCA group 22  
 P<sub>2</sub>–P<sub>3</sub> butanediamide inhibitors 43  
 P<sub>2</sub>–P<sub>3</sub> butanediamide renin inhibitors 44  
 Paclitaxel–peptide conjugates 172

- Palinavir 45, 46  
 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocoline (POPC) 179  
 Palmitoyl-DL-carnitine chloride 79  
 Pancreatic polypeptide (PP) 253, 262  
 Pan-drug resistant microbes 91  
 Panitumumab 339  
 Paracellular transport 75  
 Parasympathetic nervous system (PNS) 249  
 Parkinson's disease 281–82  
 Particle replication in non-wetting templates (PRINT) technique 83, 84  
 Particulate carrier systems 83–84  
 Patenting 65  
 Patents 61–63  
 Pathogenesis-related (PR) proteins 140  
 PC-1505, 221  
 PCT level 62  
 PCT patent 62  
 PDC1 protein 149  
 Pegasparaginase 194  
 PEG-epoetin beta (Mircera<sup>®</sup>) 190  
 Pegfilgrastim (Neulasta<sup>®</sup>) 190, 194, 197  
 Peg-interferon 194  
 PEGylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) 190  
 PEGylation 81, 347  
 PepT1 82  
 PepT2 82  
 Peptibodies 192  
 Peptide fusion inhibitors and respective gp41 domains 214  
 Peptide mimics 3  
 Peptide sequencing 120–21  
 Peptide stability to proteolytic digestion by trypsin 106  
 Peptide YY (PYY) 253  
 Peptide–membrane partition studies, BBB permeability with 179  
 Peptides transformation to peptidomimetics 5–7  
 Peptidomimetics 3  
 – peptides transformation to 5–7  
 Peptidyl segment, optimized 10–12  
 Peptidyl-activated carbonyl inhibitors 14  
 Peripheral blood lymphocytes (PBL) 328  
 Peripheral hyperinsulinemia 71  
 Peripherally secreted neuropeptides  
 – amylin 256–57  
 – bombesin-like peptides 257–58  
 – cholecystokinin (CCK) 258–59  
 – ghrelin 259–60  
 – glucagon-like peptide-1 (GLP-1) 260–61  
 – leptin 261–62  
 – oxyntomodulin (OXM) 262  
 – PYY3-36 and pancreatic polypeptide (PP) 262–63  
 Permeation enhancers 77, 78  
*Petunia* 140  
*Petunia hybrida* 140  
 Pexelizumab 343  
 Pfizer 343  
 Pg-AMP1 144  
 P-glycoprotein-like mechanisms 76  
 Phage-display screening 3  
 Pharmacodynamics (PD) 194–99  
 Pharmacokinetics (PK) 194–99  
 Phenol red 298  
 Phenols 145  
 Phentermine 299, 304  
 Phentermine hydrochloride 304  
 Phosphatidylinositol-3 kinase (PI-3K) 260  
 Phosphatidylcholine (PC) 236  
 Phosphatidylserine (PS) 183  
 Physicochemical properties of peptide drugs 73  
 Phytoconstituents 80  
*Phytophthora parasitica* f. sp. *nicotianae* 148  
*Pichia pastoris* 148, 149  
*Pisum sativum* 141  
*Pisum sativum* defensin1 (rPsd1) 149  
 Plant antimicrobial peptides 139–50  
 – biotechnological products produced from 144–50  
 – diversity of 139–40  
 – structural folds in 140–44  
 Poly(acrylic acid) 84  
 Poly(acrylic acid) derivatives 79  
 Polyalanine 314  
 Polyclonal human IgG (IVIG) 316  
 Poly-DL-alanine 313  
 Polyethylene glycol (PEG) 81, 172, 346  
 Poly-L-lysine 313  
 Polylysine 313  
 Polymers 79  
 Polymyxins 91  
 Polypeptide immunomodulator  
 – drug for multiple sclerosis 316–27  
 Polyploid cells 189  
 Polysorbate 80 79  
 POPG (1-palmitoyl-2-oleyl-sn-glycero-3-(phosphor-rac-(1-glycerol))) 179  
 Post-infectious gastroparesis 279  
 Post-prandial hyperglucagonemia 297, 298  
 – and diabetes 297  
 Post-transcriptional gene silencing (PTGS) 150

- Posttranslational modification (PTM) 122–24  
 Prader–Willi syndrome 259, 262  
 Pramlintide 257, 296, 298, 302, 304, 306  
 – weight lowering effects of 303  
 Pramlintide/metreleptin 306  
 Proboscis 119  
 Prodrug strategies for peptide drugs 80  
 Prodynorphin (PDYN) 255  
 Proenkephalin (PENK) 255  
 Prohormone convertase 1 (PC1) 260  
 Prohormone convertase 2 (PC2) 260  
 Prokaryotic membranes  
 – and antimicrobial peptides 93  
 Prokaryotic system 146  
 Prokinetics 283  
 Pro-opiomelanocortin (POMC) 250,  
 252, 255  
*Propionibacterium acnes* 162, 164  
 Protease inhibitors 209  
 Protein and antibody scaffolds 344  
 Protein folding 127  
 Protein kinase C 273  
 Protein transduction domains. *See* Cell  
 penetrating proteins  
 Proteinases 141  
 Proteomics 171  
 Proton pump inhibitors (PPIs) 283  
 PRS-050 344  
*Pseudomonas aeruginosa* 91, 106, 107, 109  
*Pseudomonas aëuroginosa* 64  
*Pseudomonas syringae* 59  
 PTGS-MAR 150  
 PubMed 172  
 PYY3-36 and pancreatic polypeptide  
 (PP) 262–63  
  
 QRFP 256  
 Quinones 145  
  
 Radioablation treatment 283  
 Radio-labeled nutrients 298  
 Ranibizumab 342  
*Raphanus sativus* 141  
 Raptiva 339  
 Receptor activity modifying protein  
 (RAMP) 256  
 Re-engineered conotoxins, in drug  
 design 131–33  
 Remicade 339  
 Renin 38–44  
 – aspartyl protease renin as a  
 target 38–44  
 – inhibitors 42, 75  
 Renin-angiotensin 38  
  
 ReoPro 339  
 Retinoids 166  
 Reverse transcriptase 209  
 Reversed-phase high performance liquid  
 chromatography (RP-HPLC) 96–98, 99,  
 100  
*Rhizoctonia solani* 148  
 rHuTPO 190  
 Ribavirin 30  
 Ribonucleotide reductase (RR) 32  
 Ribonucleotide reductase inhibitors 32–38  
 Risk Evaluation and Mitigation Strategy  
 (REMS) 203  
 Rituxan 339  
 Rituximab 338  
 Rodents, amylin agonism in 295–309  
 Romiplostim (Nplate<sup>®</sup>) 189–205  
 – brief ITP primer 199–201  
 – diagnosis and treatment 199–200  
 – thrombopoietin and ITP 200–201  
 – clinical data 201–3  
 – design and development 203–5  
 – discovery and optimization of 192–94  
 – pharmacodynamics and  
 pharmacokinetics 194–99  
 – thrombopoietin and c-Mpl 189–92  
 Rosacea, treatment of 166  
 R-site peptide 9  
 rTvD1 peptide 148  
  
*Saccharomyces cerevisiae* 80  
 2S albumins 143  
 SAR studies 10  
 SBI-087 343, 344  
 SC34 216–17  
 SC34EK 216–17, 217  
 “Sensemaking” phase 3, 5  
 Serine proteases 10  
 “Sham” feeding 300  
 Shepherins 140  
 Sibutramine 299, 304  
 Sibutramine hydrochloride 304  
 Sifuvirtide 215, 222, 223, 231–41  
 – efficiency by biomembrane selectivity  
 236–37  
 – high potency of 234–35  
 – limited drug resistance 235–36  
 – monotherapy, stratification of 238–39  
 – pharmacokinetics with long half-life 237–  
 38  
 – structure-based drug design of 232–34  
 Signal transducer and activator of  
 transcription-3 (STAT3) 261  
 Simulect 339

- Single-domain antibodies 343–45  
 Sinomenine 78, 80  
 Small molecule agents, and amylin agonism 304  
 SME (small and medium-sized enterprise) 68  
 Snakin-1 (sn1) 148  
 Snakins 140  
 Sodium caprate 79  
 Sodium caprylate 79  
 Sodium cholate 79  
 Sodium deoxycholate 79  
 Sodium dodecylsulfate 79  
 Sodium laurate 79  
 Sodium taurocholate 79  
 Solid phase peptide synthesis (SPPS) 124  
 Specificity determinants 94, 100, 104  
 Spin-off creation 64–68  
 Spp-100 44  
*Staphylococcus aureus* 63, 91, 106  
*Staphylococcus aureus*, effect of omiganan treatment on 161  
*Staphylococcus epidermidis* 106  
*Streptomyces* 315  
 Streptozotocin-treated rats 298  
 Structural folds, in plant AMPs 140–44  
 Structure–activity relationship (SAR) 29, 34  
 Substrate peptides, mapping essential elements of 8–10  
 Sulfhydryl (SH) group 81  
*Suncus murinus* 274  
 Suppressor of cytokine signaling-3 (SOCS-3) 261  
 Suprachiasmatic nucleus (SCN) 254  
 Supraoptic nucleus (SON) 260  
 Surfactants 79  
 Sympathetic nervous system (SNS) 249  
 Synagis 339  
 Synthetic C-peptides 211  
 Synthetic N-peptides 211  
 Systemic lupus erythematosus (SLE) 328  
 – peptides therapy for 328–29  
  
 T-1144 223  
 T-1249 211, 214–15, 223  
 T-20. *See* Enfuvirtide  
 T-2410 218  
 T-651 221  
 Tachygastria 282  
 Tachyphylaxis 271, 273  
 Tandem mass spectrometry (MS/MS) 120  
 Tannins 145  
 t-Butoxycarbonyl (Boc) 126  
 T-cell epitopes 314  
 TechnoAntibodies 345  
 Technology transfer  
 – in marketing antimicrobial peptides 64–66  
 Technophage 345  
 Tekturna 44  
 Tephrosia villosa 148  
 Terpenoids 145  
 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 176  
 Tetrapeptides 22  
 TGF- $\beta$  321, 327  
 Th1 cytokines 320  
 Th2 cells 320  
 T-helper (Th) 320  
 Therapeutic antibodies 337, 338  
 Therapeutic monoclonal antibodies, in United States 339  
 $\gamma$ -thionins 141  
 Thioredoxin (Trx) 148  
 Threonine 233  
 Thrombopoietin (TPO) 190  
 – and c-Mpl 189–92  
 Tifuvirtide 211  
 Tipranavir 46, 47  
 Tissue localization and plant species distribution  
 – in plant AMPs 139–40  
 TNF-specific antibodies 347  
 Toll-like receptor (TLR)-2 327  
 Toroidal pore model 92  
 Tosylation 60  
 Transcytosis 82  
 Transdermal delivery system 172  
 Transferred NOESY model 25  
 Transforming growth factor (TGF) 320  
 Transforming growth factor- $\beta$  (TGF- $\beta$ ) 328  
 Trifluoroacetic acid (TFA) 126  
 Trifluoroethanol (TFE) 102  
 Trifluoromethylketone analogs 17  
 Trifluoromethylketone N-peptide 18  
 Trimeris, Inc. 211, 221  
 Trinitrobenzene sulfonic acid (TNBS)-induced colitis 326  
*Triticum aestivum* 141  
 “Trojan horse” technology 174  
 Trojan peptides. *See* Cell penetrating proteins  
 Trp/Phe 173  
 TRU-015 343  
 Trubion Pharmaceuticals 343  
 Tuftsin 315  
 Tumor-associated antigens (TAA) 315  
 TvD1 148  
 L-Tyrosine 313, 317  
 Tysabri 339  
 TZP-101 276, 277, 284

- Ubiquitin 148
- UBQ 149
- UCB 342
- UL80 gene 7
- Ulimorelin 284
- Unstirred water layer 73–74
- Urocortins 249
  
- V13 96, 98, 103
  - with D-Ala (V13A<sub>D</sub>) 104
- V13K 98, 99, 103
  - D enantiomer of 106
- V13L 110
- V681 96
- Vagotomy 276
- Valorization 64–66
- Vancomycin 171
  - vancomycin-resistant *Staphylococcus aureus* (VRSA) 163
- Variable heavy chains (VHH), of antibodies 343
- Varicella zoster virus (VSV) RR 38
- Vc1.1 130
- Ventromedial hypothalamus (VMH) 250
- Verapamil 79
  
- Verticillium dahliae* 149
- Vicilin-like AMPs 140
- Vigna radiata* 141
- Vigna unguiculata* 148
- Vincristine 200
- Voltage-gated calcium channel (VGCC) 121
- Voltage-gated potassium channel (VGKC) 121
- Voltage-gated sodium channel (VGSC) 121
- VrD1 141
- VuD1 148
  
- “Warhead” strategy 10
- Whole leaf 80
- World Health Organization 171
- Wyeth 346
  
- Xanthomonas vesicatoria* 59
- Xenopus* oocytes 130
- Xolair 339
- X-ray crystallographic analyses 7
  
- Zenapax 339
- Zevalin 339, 346
- Zonula occludens toxin (ZOT) 78, 79